There are two major types of inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC). Conflicting reports have indicated that the soluble factor IL-22 can have both IBD promoting and IBD controlling effects. But now, Atsushi Mizoguchi and colleagues at Massachusetts General Hospital, Boston, have established that IL-22 ameliorates disease in a mouse model of UC.
Expression of IL-22 is much higher in the intestines of individuals with CD than UC. To investigate the role of IL-22 in IBD, the authors used a new microinjection-based strategy to deliver the gene that makes IL-22 to the walls of the intestine of mice who suffer from an intestinal disease that models UC. Delivery of the Il-22 gene ameliorated local intestinal inflammation through enhanced mucus production. Consistent with this, when the same strategy was used to deliver a gene that makes a protein that neutralizes IL-22, IL-22–binding protein, to the walls of the intestines of normal mice it enhanced chemical-induced intestinal inflammation. The authors therefore suggest that individuals with UC might benefit from local delivery of the IL-22 gene to their intestines.
TITLE: IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Phone: (617) 726-2588; Fax: (617) 726-2365; E-mail: email@example.com.
View the PDF of this article at: https://www.the-jci.org/article.php?id=33194
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.